Visible results with DUPIXENT
Actual patients in a Phase 3 pediatric DUPIXENT trial (AD-1652). All patients were prescribed concomitant TCS based on the clinical trial program. Patients 1, 2, and 3 were considered clinical responders. Individual results may vary.
In DUPIXENT clinical trials including children, the primary endpoint was the change from baseline to Week 16 in the proportion of subjects with an Investigator's Global Assessment (IGA) of 0 (clear) or 1 (almost clear).1
Patient 1: 6-year-old achieved a 3-point improvement in IGA2
to see results
Patient 2: 10-year-old achieved a 3-point improvement in IGA2
to see results
Patient 3: 9-year-old achieved a 3-point improvement in IGA2
to see results
Patient 4: 6-year-old achieved a 1-point improvement in IGA
to see results
A clinical responder was defined as a patient achieving IGA 0 or 11
- Patient 4 did not meet the primary endpoint in the clinical trial based on their IGA score at Week 16
Clearer skin demonstrated in children
aFull Analysis Set includes all subjects randomized.
bIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.
cAt Day 1, subjects (baseline weight <30 kg) received 600 mg of DUPIXENT.
dAt Day 1, subjects (baseline weight ≥30 kg) received 400 mg of DUPIXENT.